ETF's That Let You Trade the Volatility Index "VIX"

Matt Thalman - INO.com Contributor - ETFs


One of the many great side effects to the rise in popularity of Exchange Traded Funds, ETF's, is that they have increased the types of investments individuals can buy into. The average investor can now easy buy and sell funds that hold actual commodities, indexes, bond portfolios, and even dabble in the options markets without ever making a signal put or call trade themselves.

Today, I would like to point out how investors can use ETF's to play the S&P 500 Volatility Index or VIX.

But, before we get into the ETF's that allow you to profit from the VIX's moves, let take a look at the VIX itself and what causes it to move in one direction or the other. The VIX is calculated using option pricing. It looks at the price of the call and put options because we know that higher option prices mean that investors believe there is a greater chance of volatility. Without getting into too much detail about options, the reason this works is because if an underlying security has high volatility it can make an option more or less valuable depending on what side of the trade you are on. Because the level of volatility will change the likelihood, the option will expire in or out of the money.

Are you confused yet? Continue reading "ETF's That Let You Trade the Volatility Index "VIX""

Is This ETF Signaling Trouble Ahead?

Hello MarketClub members everywhere, today I'm going to be looking at SPDR Gold Shares (PACF:GLD) and showing you why it could be signaling trouble ahead for stocks, the economy and a whole host of other challenges.

GLD did something that was unusual recently by breaking over a three-year trendline. As you approach and trade the market in a technical manner, this is a significant event that should not be overlooked.

Another interesting aspect to GLD is that it just completed a 61.8% Fibonacci retracement from its all-time high. I'm going to be looking at GLD in detail today and I will give you my precise analysis of this market and the reason why I think it can go significantly higher in the next 3 to 6 months.

I will also be analyzing the major indices and why they have been so choppy recently along with crude oil, the dollar and gold.

I highly recommend that you take a few minutes out of your day and watch the video!

Stay strong and disciplined.

Every success with MarketClub,
Adam Hewison
President, INO.com
Co-Creator, MarketClub

How To Invest Alongside "Shark Tanks" Kevin O'Leary

Matt Thalman - INO.com Contributor - ETFs


Up until just a few years ago the name Kevin O'Leary didn't mean much to most investors. But, with O'Leary starring on the hit TV show "Shark Tank", now most investors, as well as the general public at least, recognize the name. Furthermore, if you often watch Shark Tank you likely have a good idea of how "Mr. Wonderful", O'Leary's nickname on Shark Tank, likes to invest.

Mr. O'Leary often asks for a royalty deal, a few dollars every time an item is sold when giving entrepreneurs money. While some of the other investors on the show often criticize O'Leary for building in the royalty deal, claiming he is taking advantage of people, the idea behind the royalty is so that O'Leary can get his initial investment back in a reasonable amount of time. Furthermore, it acts as a safety net for O'Leary if the company he invests in is a massive winner at first but, doesn’t have the longevity to grow and become a long-term successful organization.

While the sarcastic nickname O'Leary has received on the show may not make him the best partner for an entrepreneur, it shows that he not only is a wise investor but someone that limits their risk as much as possible. For some investors, this sounds like the kind of guy they would love to be able to invest with. I mean honestly, who hasn’t watched Shark Tank and thought to themselves how cool it would be if they could partner with one of the investors on the show?

Well, you know can! Continue reading "How To Invest Alongside "Shark Tanks" Kevin O'Leary"

A New Immunotherapy ETF Has Launched

Noah Kiedrowski - INO.com Contributor - Biotech


Update

I previously wrote an article laying the groundwork for an exciting immunotherapy ETF launching in the second half of 2015, “A Niche ETF In The Potentially Promising Future Of Immunotherapy Is On The Horizon.” Loncar Investments has teamed up with an ETF firm and finally launched its immunotherapy ETF, Loncar Cancer Immunotherapy ETF (ticker symbol: CNRC). I wanted to update readers on the latest information and launch of the ETF as many readers requested.

Introduction

Immunotherapy has emerged as an exciting therapeutic area that has experienced massive growth over the past few years in terms of research and development expenditures and a sheer number of clinical trials throughout the biotechnology sector. Immunotherapy ushers in a new class of potentially promising therapies by leveraging the immune system to recognize and eradicate debilitating diseases, specifically cancer and chronic viral infections. This immunotherapy approach may inevitably result in a paradigm shift from traditional medical intervention. Immunotherapy possesses holistic attributes by harnessing the body’s immune system to contend with the disease. Continue reading "A New Immunotherapy ETF Has Launched"

6 Ways To Play The Biotech Industry Moving Forward

Matt Thalman - INO.com Contributor - ETFs


In September Biotech stocks got hammered. Most market participants blamed the massive decline on Democratic Presidential candidate Hillary Clinton. On September 21, Clinton tweeted "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." Clinton was referring to a drug called Daraprim, a 65-year-old drug, which recently saw its price increase from $13.50 per pill to $750.

While there are arguments for and against why Daraprim and other drugs increase in price, an industry-wide reform on how prices are set would likely hurt nearly every company in the biotech space. And that was what Clinton essentially proposed last month. With uncertainty surrounding the industry, the NASDAQ Biotechnology Index (NBI) fell by more than 15% just in September compared to a decline of just 4.4% for the S&P 500 during the month. Continue reading "6 Ways To Play The Biotech Industry Moving Forward"